N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof
Pharmaceutical compositions including an amorphous N—N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.
1. A mucoadhesive therapeutic composition comprising:
a pharmaceutically effective amount of an active DMT agent, the active DMT agent comprising N, N-dimethyltryptamine or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically effective amount of the active DMT agent is about 0.5% to about 60% by weight of the mucoadhesive therapeutic composition; and
a polymeric carrier matrix,- the polymeric carrier matrix stabilizing the DMT agent in an amorphous form within the mucoadhesive therapeutic composition, wherein the polymeric carrier matrix is present in the mucoadhesive therapeutic composition in an amount of 15 to 80 percent by weight of the mucoadhesive therapeutic composition, the polymeric carrier matrix comprising at least one cellulose derivative and a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate, the cellulose derivative being selected from hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, or combinations thereof,
wherein the stabilization of the DMT agent in an amorphous form is characterized by a powder x-ray diffractogram free of any discernable peaks that are attributable to the active DMT agent.
2. The mucoadhesive therapeutic composition of claim 1 , wherein the mucoadhesive therapeutic composition is suitable for buccal or sublingual administration.
3. The mucoadhesive therapeutic composition of claim 1 , wherein the mucoadhesive therapeutic composition is characterized by a differential scanning calorimetry (DSC) spectrum lacking a sharp melting endotherm of crystalline DMT and/or lacking an indication of phase change.
4. The mucoadhesive therapeutic composition of claim 1 , wherein the pharmaceutical composition is capable of producing a T max between 10 min to 90 min upon administration.
5. The mucoadhesive therapeutic composition of claim 1 , wherein the polymeric carrier matrix further comprises polyacrylic acid, polyacrylate, polyethylene oxide, polyvinyl alcohol, propylene glycol alginate ester, tragacanth, alginate, a gum, a soluble starch, gelatin, lectin, pectin, or chitosan, or a mixture thereof.
6. The mucoadhesive therapeutic composition of claim 1 , wherein the mucoadhesive therapeutic composition comprises
about 0.1% to about 30% by weight of a permeation enhancer.
7. The mucoadhesive therapeutic composition of claim 1 , wherein the pharmaceutically effective amount of the active DMT agent is about 0.5% to about 60% by weight of the mucoadhesive therapeutic composition.
8. The mucoadhesive therapeutic composition of claim 1 , wherein the polymeric carrier matrix is present in the mucoadhesive therapeutic composition in an amount of 50 to 60 percent by weight of the mucoadhesive therapeutic composition.
9. The mucoadhesive therapeutic composition of claim 1 , further comprising 0.5% to 20% by weight of a plasticizer.
10. The mucoadhesive therapeutic composition of claim 1 , further comprising 0.1% to 10% by weight of a buffering agent.
11. The mucoadhesive therapeutic composition of claim 1 , further comprising 0.1% to 5% by weight of an antioxidant.
12. The mucoadhesive therapeutic composition of claim 6 , wherein the polymeric carrier matrix comprises hydroxypropyl cellulose, a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate, and hydroxypropyl methylcellulose.
13. The mucoadhesive therapeutic composition of claim 1 , wherein DMT or a pharmaceutically acceptable salt thereof is capable of being substantially fully solubilized and released in greater than 1 minute and less than 40 minutes following administration of the composition to a patient in need thereof.
14. An oral transmucosal film comprising the mucoadhesive therapeutic composition of claim 1 .
15. The oral transmucosal film claim 14 , wherein the oral transmucosal film has a thickness that is 0.01 mm to 1.5 mm.
16. A method of treatment of a disease or disorder, the disease or disorder being an anxiety disorder or mood disorder, wherein the method comprises administering a therapeutically effective amount of the composition of claim 1 to a patient in need thereof.
17. The method of claim 16 , wherein the administration is sublingual or buccal.
18. The mucoadhesive therapeutic composition of claim 1 , wherein the composition further comprises a buffering agent and an antioxidant.
19. The method of claim 16 , wherein the disease or disorder is treatment-resistant depression.
20. A mucoadhesive bilayer film product comprising
the oral transmucosal film of claim 14 ; and
an inactive backing layer.